PRESERVE: Pegaptanib for Retinal Edema SEcondaRy to diabetic Vascular diseasE

Diabetic Macular Edema (DME) occurs when normal retinal blood vessels become damaged and leak both fluid and protein. This leakage distorts normal retinal architecture and leads to decreased visual acuity.

Previous studies have shown that a peptide called VEGF165 is predominant in patients with DME. High levels of VEGF165 may cause the development and progression of diabetic macular edema and retinopathy.

The purpose of this study is to evaluate the optimal dosing frequency of Macugen in eyes with Diabetic Macular Edema.

This study will involve men and women age 18 and older. Participation in the study will last approximately 24 weeks.

Contact the PRESERVE enrollment contact number at (316) 712-4988 if you believe you might qualify to participate in PRESERVE.